CareLit Fachartikel

Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study

Milka Marinova, Reza Alamdar, Hojjat Ahmadzadehfar, Markus Essler, Ulrike Attenberger, Martin Mücke, Rupert Conrad · Nuklearmedizin - NuclearMedicine · 2020 · Heft 06 · S. 409-414

Dokument
869065
CareLit-ID
Jahr
2020
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Nuklearmedizin - NuclearMedicine
Autor:innen
Milka Marinova, Reza Alamdar, Hojjat Ahmadzadehfar, Markus Essler, Ulrike Attenberger, Martin Mücke, Rupert Conrad
Ausgabe
Heft 06 / 2020
Jahrgang 59
Seiten
409-414
Erschienen: 2020-12-01 00:00:00
ISSN
0029-5566
DOI
10.1055/a-1234-5891

Zusammenfassung

Abstract Introduction To evaluate the clinical therapeutic response of PSMA targeted radioligand therapy with 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. The current study analyzed disease-related quality of life (QoL) in patients undergoing PSMA therapy with a special focus on the association with simultaneous PSA response. Methods Thirty patients (age range 50–87 years, median 73.5 years) undergoing 177Lu-PSMA-617 therapy from 2014 to 2016 at our institution were included in this pilot study. Health-related QoL was assessed by EORTC QLQ-C30 questionnaire filled in at baseli…

Schlagworte

metastatic prostate cancer 177Lu-PSMA-617 radioligand therapy quality of life EORTC QLQ-C30 Metastasiertes Prostatakarzinom Radioliganden Therapie Lebensqualität Nuklearmedizin - NuclearMedicine